Description: Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, recombinant albumin in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. Its APIs also include nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company provides intermediates; high-purity multi-cyclic and long-chain peptides; specialty and biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, orally disintegrating films, transdermal patches, and lyophilized injectables. Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.
Home Page: www.vbshilpa.com
Shilpa House
Raichur,
584135
India
Phone:
91 85 3223 8704
Officers
| Name | Title |
|---|---|
| Mr. Vishnukanth Chaturbhuj Bhutada B. Pharm | MD & Director |
| Mr. Alpesh Maheshkumar Dalal | Chief Financial Officer |
| Mr. Sharath Reddy Kalakota M.Pharma | VP of Projects & Operations and Whole-Time Director |
| Ms. Ritu Tiwary | Company Secretary & Compliance Officer |
| Dr. Jayant Karajgi | Chief Operating Officer of Formulations |
| Dr. Ganeshchandra Sonavane | President of Global R&D |
| Mr. Rajeev Saxena | Senior Vice President ? Domestic Formulations and Biologics |
| Mr. Abhay Sapre | Senior Vice President of Formulation |
| Ms. Smita Holey | Executive Vice President ? Formulations for Small Molecules |
| Mr. Awez Mohinuddin Pathan | Vice President |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 158.7302 |
|---|---|
| Trailing PE: | 128.2684 |
| Price-to-Book MRQ: | 3.594 |
| Price-to-Sales TTM: | 7.0691 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 1007 |